Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ; KEYNOTE-040 investigators. Cohen EEW, et al. Among authors: mach n. Lancet. 2019 Jan 12;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8. Epub 2018 Nov 30. Lancet. 2019. PMID: 30509740 Clinical Trial.
Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study.
Lin CC, Curigliano G, Santoro A, Kim DW, Tai D, Hodi FS, Wilgenhof S, Doi T, Sabatos-Peyton C, Szpakowski S, Chitnis S, Xyrafas A, Gutzwiller S, Pastore A, Mach N. Lin CC, et al. Among authors: mach n. BMJ Open. 2024 Aug 29;14(8):e079132. doi: 10.1136/bmjopen-2023-079132. BMJ Open. 2024. PMID: 39209782 Free PMC article. Clinical Trial.
Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors.
Curigliano G, Curigliano H, Mach N, Doi T, Tai D, Forde PM, Sarantopoulos J, Bedard PL, Lin CC, Hodi FS, Wilgenhof S, Santoro A, Sabatos-Peyton CA, Longmire TA, Xyrafas A, Sun H, Gutzwiller S, Manenti L, Naing A. Curigliano G, et al. Among authors: mach n. Clin Cancer Res. 2024 Sep 3;30(17):3957. doi: 10.1158/1078-0432.CCR-24-2131. Clin Cancer Res. 2024. PMID: 39224022 No abstract available.
Comparison between 16S rRNA and shotgun sequencing in colorectal cancer, advanced colorectal lesions, and healthy human gut microbiota.
Bars-Cortina D, Ramon E, Rius-Sansalvador B, Guinó E, Garcia-Serrano A, Mach N, Khannous-Lleiffe O, Saus E, Gabaldón T, Ibáñez-Sanz G, Rodríguez-Alonso L, Mata A, García-Rodríguez A, Obón-Santacana M, Moreno V. Bars-Cortina D, et al. Among authors: mach n. BMC Genomics. 2024 Jul 29;25(1):730. doi: 10.1186/s12864-024-10621-7. BMC Genomics. 2024. PMID: 39075388 Free PMC article.
A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors.
Vernet R, Fernandez E, Migliorini D, Ancrenaz V, Charrier E, Belkouch MC, Von Rohr O, Urwyler M, De Vito C, Renaux J, Villard J, Rubin O, Grogg J, Mach N. Vernet R, et al. Among authors: mach n. Cancer Res Commun. 2024 Aug 1;4(8):2089-2100. doi: 10.1158/2767-9764.CRC-24-0150. Cancer Res Commun. 2024. PMID: 39041242 Free PMC article. Clinical Trial.
157 results